4 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow matuzumab: new trials by email Literature Review of matuzumab trials Research Report on matuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer Matuzumab, Epirubicin, Cisplatin - Esophageal Cancer, Gastric Cancer | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 72 | 2005-08-31 | 2018-11-02 |
| Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer Pemetrexed, Matuzumab - Lung Cancer, Non Small Cell Lung Carcinoma | Phase 2 | Completed | EMD Serono | 150 | 2005-05-31 | 2018-04-06 |
| A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer EMD 72000 - Ovarian Cancer | Phase 2 | Completed | EMD Serono | 38 | 2003-04-01 | 2017-01-20 |
| Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer EMD 72000 (matuzumab) + ECX - Esophageal Cancer, Gastric Cancer | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 26 | 2002-10-01 | 2014-02-19 |
Esophageal Neoplasms (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Ovarian Neoplasms (1)
EMD Serono (2) · Merck KGaA, Darmstadt, Germany (2)
Germany (2) · United Kingdom (2) · United States (2) · Austria (1) · Spain (1) · Switzerland (1)
David Cunningham, Professor (1)
PMID 17126894, PMID 20497967, PMID 20978446
2005 (1)